Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | PLAU | P00749 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479593 | 0.87 | PARP1 (0.78) | NPC1RAB9APLAUPARP1ALOX5 | |
| SCHEMBL10631530 | 0.85 | ALOX5 (0.55) | NPC1RAB9APLAUMAP4K4TAAR1 | |
| SCHEMBL22367342 | 0.84 | MKNK1 (0.64) | PARP1MKNK1MKNK2DHODH | |
| SCHEMBL2040947 | 0.83 | RXRA (0.69) | MAP4K4TAAR1ALOX5 | |
| SCHEMBL2589651 | 0.82 | ERN1 (0.60) | PARP1MKNK1MKNK2DHODH | |
| SCHEMBL5952278 | 0.82 | RXRA (0.68) | NPC1RAB9APARP1MKNK1MKNK2 | |
| SCHEMBL10799811 | 0.81 | SMN1; SMN2 (0.62) | NPC1RAB9APLAUTAAR1ALOX5 | |
| SCHEMBL3723969 | 0.81 | PARP1 (0.63) | PLAUPARP1MAP4K4RORCDHODH | |
| SCHEMBL2689662 | 0.80 | MAP4K4 (0.72) | MKNK1MKNK2MAP4K4IKBKB | |
| SCHEMBL30927156 | 0.80 | MKNK1 (0.60) | NPC1RAB9APLAUPARP1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872947-B | Benzisothiazole benzamide compound or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | NPC1 1316/4885RAB9A 4538/4885PLAU 542/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | NPC1 896/4885RAB9A 3868/4885PLAU 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.